Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 16, 2024; 12(5): 942-950
Published online Feb 16, 2024. doi: 10.12998/wjcc.v12.i5.942
Published online Feb 16, 2024. doi: 10.12998/wjcc.v12.i5.942
Clinical efficacy and mechanism study of mid-frequency anti-snoring device in treating moderate obstructive sleep apnea-hypopnea syndrome
Bao Qian, Zhan-Jun Chen, Xiao-Yan Hu, Xiao-Biao Hu, Yong-Hua Zheng, Pulmonary Medicine, Shanghai Jinshan Tinglin Hospital, Shanghai 201505, China
Yong-Sheng Wang, Radiology Medicine, Shanghai Jinshan Tinglin Hospital, Shanghai 201505, China
Co-first authors: Bao Qian and Zhan-Jun Chen.
Author contributions: Qian B and Chen ZJ contributed equally to this work; Qian B and Chen ZJ performed the study; Wang YS performed the computed tomography scan examination; Hu XY and Hu XB analyzed the data; Zheng YH designed the research and wrote the manuscript; all authors read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of the Shanghai Jinshan Tinglin Hospital (Approval No. 2022-06-01).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent before enrollment.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Hua Zheng, MD, Deputy Chief Physician, Pulmonary Medicine, Shanghai Jinshan Tinglin Hospital, No. 80 North Siping Road, Jinshan District, Shanghai 201505, China. zhengyonghua0118@hotmail.com
Received: November 2, 2023
Peer-review started: November 2, 2023
First decision: December 5, 2023
Revised: December 14, 2023
Accepted: January 23, 2024
Article in press: January 23, 2024
Published online: February 16, 2024
Peer-review started: November 2, 2023
First decision: December 5, 2023
Revised: December 14, 2023
Accepted: January 23, 2024
Article in press: January 23, 2024
Published online: February 16, 2024
Core Tip
Core Tip: We investigated the clinical efficacy and underlying mechanisms of a mid-frequency anti-snoring device in treating 50 moderate obstructive sleep apnea-hypopnea syndrome patients for 4 wk. Our results indicated significant improvements in the apnea-hypopnea index, the percentage of time with oxygen saturation below 90%, and the sleep apnea quality of life index and Epworth Sleepiness Scale scores. Additionally, we found compelling evidence that the mid-frequency anti-snoring device positively influenced the narrowing of the oropharynx in sleep apnea-hypopnea syndrome patients during snoring.